The vasopressin type 2 receptor promotes dual Gα_s and Gα_q/11 signaling at early endosomes in β-arrestin-dependent and -independent manners.

SARS-CoV-2 infection and vaccination elicit antibodies that cross-react with other human coronavirus spike proteins, indicating the spike S2 subdomain as a potential target strategy to develop a pan-coronavirus vaccine.

Transcriptomic comparison of inflammatory and steady-state osteoclasts reveals differences in their ability to sense their environment, which makes it possible to selectively inhibit inflammatory osteoclastogenesis and reduce bone loss in osteoporosis.

A novel EAE model featuring cortical lesions and an autoimmune heterogeneity, two key parameters missing in the classical model, allows for insights in disease pathogenesis.

Non-neutralizing antibodies to the SARS-CoV-2 spike protein’s S2 domain that also recognize widely circulating endemic coronavirus strains are rapidly boosted by natural infection but not vaccination with stabilized spike-based vaccines.

An experimental animal model provides further insights into the host and viral mechanisms underlying airborne transmission of SARS-CoV-2.

Class 1 histone deacetylase (HDAC) inhibitor MS-275 enhances the efficacy of glucagon-like peptide 1 receptor (GLP-1R) therapy for glycemic control and reduction of obesity.

Treatment with a JAK inhibitor normalizes multiple biomarkers of autoinflammation and provides therapeutic benefit for diverse immune skin conditions in individuals with Down syndrome.